vincristine / Generic mfg. - LARVOL DELTA

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

Vincristine-induced neuropathy: Long term follow-up of lymphoma survivors treated with CHOP or dose-adjusted EPOCH chemotherapy (ASH 2025) - "Introduction: The incidence of Vincristine-induced neuropathy (VIN) occurs in up to 70% of non Hodgkin Lymphoma (NHL) survivors treated with front-line lymphoma regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and infusional dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), administered with or without rituximab (R) (Su et al., 2025). Overall, neuropathy outcomes varied in our cohort. For most, CIPN20 scores were stable to improved between T3 and T4, yet 3 participants (mean age 68.7) reported persistent numbness and tingling in their feet and toes. Increasing age has been reported as a risk factor for development of chemotherapy induced neuropathy with one study reporting persistence of symptoms in the post-treatment phase (Bulls et al., 2019; Hershman et al., 2016)."

Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Pain

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Remission instead of eradication? MEK inhibition in primary refractory childhood LCH (ASH 2025) - "Patient and Methods We report on a 9-month-old infant with multisystemic LCH (thymus and cervical lymph nodes) who progressed under vinblastin/prednisone and did not respond to second-line cytarabine/vincristine therapy...This class confers resistance to first-and second generation BRAF inhibitors (e.g., Vemurafenib, Dabrafenib), which preferentially target monomeric BRAFV600E but not dimer-dependent BRAF. Functional ex vivo drug sensitivity profiling demonstarted superior tumor cell cytotoxicity of cobimetinib compared to other tested agents, including BRAF inhibitors and alternative MEK1/2 inhibitors, such as trametinib and selumetinib...However, the risk of clonal persistence underscores the need for integrated strategies. Future studies should investigate rational combinations of MEK inhibitors with senolytics and/or mTOR blockade to target both MAPK signaling and senescent cell survival, thereby suppressing SASP-related inflammation, aiming for durable molecular..."

Clinical • Hematological Malignancies • Langerhans Cell Histiocytosis • ARAF

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis (ASH 2025) - P2 | "Non-AC CITs included rituximab (R)-cyclophosphamide, doxorubicin, vincristine, prednisone [R-CEOP]/R-cyclophosphamide, vincristine, prednisone [R-CVP]/R-cyclophosphamide, etoposide, prednisone, procarbazine [R-CEPP]), bendamustine and rituximab (BR), and other combination regimens. Fixed-duration epcor mono demonstrated significantly superior OS vs non-AC regimens in newly diagnosed elderly and/or frail DLBCL pts deemed unsuitable for anthracyclines. These findings support epcor mono as a potential 1L chemo-free treatment option for newly diagnosed DLBCL pts unsuitable for AC regimens."

Clinical • Monotherapy • Diffuse Large B Cell Lymphoma • Large B Cell Lymphoma • Palliative care

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China (ASH 2025) - "Introduction: The landmark POLARIX study showed that Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) regimen was superior to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in previously untreated diffuse large B-cell lymphoma (DLBCL) with IPI 2-5. This investigation represents the first multicenter study addressing real-world outcomes of IPI 0-1 DLBCL patients treated with first-line Pola-R-CHP. Our results suggested that Pola-R-CHP showed excellent effectiveness and manageable toxicities for this specific population, even among those with adverse risk factors."

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • TP53

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma (ASH 2025) - "Introduction The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone) has been established as the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) in clinical practice...Pomalidomide, a third-generation immunomodulatory agent, exhibits more potent immunomodulatory effects compared to lenalidomide...Pomalidomide-rituximab was combined with CHOP-like regimens (n = 10), bendamustine (n = 1), brentuximab vedotin (n = 1), or BTK inhibitors (n = 2)...Grade 3-4 non-hematological AEs occurred in four patients, including one with hyponatremia and three with infections. Conclusion This real-world analysis demonstrated that the pomalidomide-rituximab-based combination therapy had promising efficacy, with a high ORR of 92.9%, in treatment-naïve DLBCL patients with extranodal disease, and exhibited acceptable hematological toxicity."

Clinical • Combination therapy • Real-world • Real-world effectiveness • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Heart Failure • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • CD5 • TP53

Utilization and tolerability of R-CHOP and R-mini–CHOP in patients with diffuse large B-cell lymphoma (DLBCL) at a community cancer center (ASH 2025) - "Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard therapy for patients diagnosed with DLBCL. R-CHOP was associated with high treatment completion and with toxicity, however there was no statistical significance in toxicities or relapse rates noted when compared to R-mini-CHOP. The underutilization of R-mini-CHOP along with significant loss to follow-up in the untreated group limited comparative assessment. These findings underscore the need for quality initiatives to expand appropriate use of R-mini-CHOP and strengthen longitudinal follow-up in community oncology settings."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients (ASH 2025) - "Introduction: R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) remains a frontline treatment for DLBCL...Pegylated liposomal doxorubicin (PLD) compared with doxorubicin has demonstrated a more favorable hematologic toxicity profile in breast cancer treatment... Patients in the R-CDOP group demonstrated greater age, lower EF, and more aggressive disease subtype than those in the R-CHOP group. There was no evidence of increased hematopoietic or cardiac adverse events in the R-CDOP group compared to the R-CHOP group. DFS was comparable while the OS was lower in the R-CDOP group, suggesting death from non-relapse etiologies."

Retrospective data • B Cell Lymphoma • Breast Cancer • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Heart Failure • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Solid Tumor • Thrombocytopenia

Metabolic tumor volume is an independent predictor of worse survival in 57 elderly patients with DLBCL (ASH 2025) - "50 (88%) patients received standard chemoimmunotherapy (CHT) (i.e. RCHOP/RCOMP), 4 (7%) reduced-intensity CHT (e.g. R-miniCHOP/COMP) and 3 (5%) intensified CHT. In elderly DLBCL patients, baseline MTV is a strong independent prognostic factor for survival, even among those achieving complete metabolic response at interim PET. Integrating MTV into PET-based response assessment may enhance risk stratification by identifying high-risk patients who might benefit from tailored therapeutic approaches."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Factors associated with achieving complete response in patients older than 65 years diagnosed with diffuse large b-cell lymphoma in first-line therapy. report from a tertiary center in Mexico city (ASH 2025) - "The most commonly used treatment was R-CHOP (59%), followed by R-miniCHOP (17%). It is important to identify factors associated with improved CR1 and OS in this age group. However, the information obtained through prospective studies needs to be confirmed and strengthened."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Palliative care

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder (ASH 2025) - "Our 61-year-old patient underwent a living-unrelated renal transplant in 2014 for focal segmental glomerulosclerosis and was maintained on mycophenolate mofetil (MMF) and cyclosporine (CsA)...MMF was discontinued, and he received four weekly doses of rituximab (375 mg/m²), achieving complete remission (CR) and was consolidated with four additional Rituximab doses by Jan 2024...After improvement of liver and kidney function, therapy was escalated to brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone (CHP), given his CD30 expression...After detailed goals-of-care discussions, he and the care team elected to proceed with additional therapy with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), since he already received azacitidine, romidepsin, and BV-CHP...His care underscores the importance of multidisciplinary collaboration, patient-centered decision-making, and longitudinal follow-up. He has been referred to our..."

Clinical • IO biomarker • Post-transplantation • Bone Marrow Transplantation • Chronic Kidney Disease • Epstein-Barr Virus Infections • Febrile Neutropenia • Focal Segmental Glomerulosclerosis • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Peripheral T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • BCL6 • CD21 • CD4 • CD5 • CD7 • ICOS • JAK1 • PD-1 • RHOA • TET2 • TNFRSF8

Survival and response rates of histone deacetylase inhibitors in peripheral T-cell lymphoma: A comprehensive systematic review and meta-analysis of 67 studies. (ASH 2025) - "It has high relapses and unfavorable prognoses with first-line chemotherapy regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone)...Currently, romidepsin, vorinostat, and belinostat have US FDA approval for the treatment of relapsed/refractory PTCL, while chidamide is approved in China but is not approved in the US...HDACi monotherapy in patients with R/R T cell lymphoma, demonstrated an ORR, with chidamide [42%; 95% CI: (0.148, 0.57), p-value = <0.00001, I2=85%] followed by romidepsin [30%; 95% CI: (0.25, 0.35), p-value = <0.00001, I2=35%], abexinostat [28%; 95% CI: (0.19, 0.37), p-value = <0.00001], belinostat [26%; 95% CI: (0.19, 0.33), p-value = <0.00001, I2=0%]... This meta-analysis demonstrates that HDACi has shown overall improved response rates and survival in PTCL patients. However, chidamide has higher response rates than romidepsin in previously treated (UT) patients. In R/R patients, complete remission is higher with romidepsin;..."

Epigenetic controller • Retrospective data • Review • Adult T-Cell Leukemia-Lymphoma • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Chidamide in combination with brentuximab vedotin for CD30+ peripheral T-cell lymphoma in patients ineligible for chemotherapy: a prospective phase II study (ASH 2025) - P=N/A | "With traditional anthracycline-based chemotherapy regimens such as CHOP (cyclophosphamide + doxorubicin + vincristine + prednisolone), approximately 70% of PTCL patients develop refractory or relapsed disease. This preliminary study demonstrates the favorable efficacy and significantly lower hematological toxicities of the BvC regimen in CD30-positive PTCL patients, offering a promising therapeutic option for this challenging population. Further updated clinical data will be shared as the study progresses."

Clinical • Combination therapy • P2 data • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • TNFRSF8

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy (ASH 2025) - "Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been the standard initial therapy for PTCL; however, clinical outcomes remain suboptimal. The introduction of brentuximab vedotin (BV)-CHP has improved survival in CD30-positive PTCL patients (pts) and has become the standard therapy for this subgroup...Of the 33 pts who subsequently received salvage therapy, 22 received at least one novel agent (e.g., BV, romidepsin, pralatrexate, tucidinostat), and 19 received conventional chemotherapy... PTCL pts who achieved CR after initial therapy demonstrated favorable long-term survival. However, more than half experienced relapse, with no clear plateau in relapse risk. This finding indicates a continued risk of relapse and highlights the need for long-term monitoring."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

Navigating classical Hodgkin lymphoma in a patient with DIAPH1 deletion syndrome: Diagnostic and therapeutic challenges in a rare immuno-genetic context (ASH 2025) - P | "He was commenced on full dose OEPA (vincristine, etoposide, prednisolone, doxorubicin) after histopathologic confirmation of cHL, and following 2 cycles his early response assessment PET showed complete metabolic response. Due to concerns about hepatic enzyme induction and mitochondrial toxicity, anti-seizure therapy was changed to levetiracetam and clobazam, as carbamazepine is a potent CYP3A4 inducer that may decrease exposure to drugs like methylprednisolone (Bartoszek et al., 1987)...This is the first report showing feasibility of full dose induction therapy for cHL with intensive supportive care in DIAPH1 deficiency. Nonetheless, ongoing careful individualised dosing, vigilant toxicity monitoring, and multidisciplinary input remain essential."

Clinical • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Disorders • Dental Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mental Retardation • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Ophthalmology • Stomatitis • CYP3A4

Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial (ASH 2025) - "Eligible patients who failed to achieve partial response (PR) after 4 cycles of 1L CIT or relapsed < 2 years were switched to O plus bendamustine and rituximab (BR). Those who achieved PR after 4 cycles or relapsed ≥ 2 years after 1L therapy received O added to the previous regimen (rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or with cyclophosphamide, vincristine, and prednisone [R-CHOP/R-CVP]) for continued treatment... Our preliminary data demonstrate that orelabrutinib in combination with rituximab-based chemoimmunotherapy is effective and well-tolerated in R/R MZL. These findings warrant further prospective studies to validate, and longer follow-up is needed to confirm PFS and OS outcomes."

Clinical • P2 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Orelabrutinib for elderly patients with stage IV marginal zone lymphoma involving the central nervous system: A case report and clinical implications (ASH 2025) - "The patient was ultimately diagnosed with mild generalized myasthenia gravis and initiated on oral tacrolimus therapy; however, no significant improvement in bilateral eyelid ptosis was observed. This case describes a rare instance of MZL with multiple extranodal involvement and CNS invasion. Its diagnostic process, therapeutic course, and outcomes carry significant reference value for the clinical management of MZL with CNS involvement. Regarding treatment, the R-miniCHOP regimen partially controlled systemic lesions, while intrathecal injections were administered to specifically clear CNS lesions."

Case report • Clinical • Metastases • CNS Disorders • Hematological Malignancies • Ischemic stroke • Lymphoma • Marginal Zone Lymphoma • Myasthenia Gravis • Myelofibrosis • Non-Hodgkin’s Lymphoma

Real-world outcomes of Mantle Cell Lymphoma in Colombia: A multicenter cohort study (ASH 2025) - "The most common induction regimens were cytarabine-based, including Rituximab - cyclophosphamide - doxorrubicin - vincristin - prednisolone (R-CHOP)/ Rituximab - dexamethasone - citarabine - cisplatin (R-DHAP) (LYMA) (46.2%, n = 37) followed by the Nordic regimen (12%, n = 10) and Bendamustine-Rituximab (BR)(10.0%, n = 8). Other treatment regimens were R-CHOP/R-miniCHOP (10.0%, n = 8), and rituximab - bendamustine - cytarabine (R-BAC) (8.8%, n = 7)...Of 39 receiving second-line therapy, 31 (44%) were treated with BTK inhibitor ibrutinib, which remains approved only for relapsed/refractory disease in Colombia... Our 5-year overall survival (OS) rate of 66.2% exceeded the 57.1% reported in a broader Latin American cohort (Pavlovsky et al., 2022), suggesting potential regional differences in outcomes. Despite the established survival benefit of autologous stem cell transplantation (ASCT), over one-third of eligible patients did not undergo transplant, highlighting ongoing..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • MYC • SOX11 • TP53

Real-world patient-based next-generation sequencing assessments identify a high-risk subgroup and associated gene signature in diffuse large B cell lymphoma (ASH 2025) - "Diffuse large B cell lymphoma (DLBCL) exhibits profound genetic heterogeneity that drives disparate clinical outcomes despite standard immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). This approach highlights previously unrecognized genes of biological and therapeutic relevance, supports early identification of relapse-prone patients and may inform personalized, risk-adapted therapy. Prospective multicenter validation and functional studies of the high-risk cluster are warranted to advance precision medicine in DLBCL."

Biomarker • Clinical • Gene Signature • Next-generation sequencing • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • ATM • B2M • CARD11 • CREBBP • KLHL6 • KMT2C • NCOR1 • NFATC1 • PDGFRB • PTEN • TET2 • TNFAIP3 • TNFRSF14 • TP53 • UBXN11

The genomic differences in hispanic vs non hispanic patients with primary central nervous system lymphoma (ASH 2025) - "The most used treatment regimen was RMPV (Rituximab, Methotrexate, vincristine and Procarbazine). We identified high rate of somatic mutations in our sample with MYD 88 being the most common mutation, except in EBV-positive PCNSL, which is consistent with previous studies reporting mutual exclusivity between MYD88 L265P and EBV-associated PCNSL. Samples from non-Hispanic patients closely resembled to C3 cluster, which may suggest a potential association between non-Hispanic ethnicity and poorer survival in our cohort. However, due to the limited sample size, no conclusions can be drawn."

Clinical • Tumor mutational burden • Brain Cancer • CNS Lymphoma • CNS Tumor • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • CD79B • CDKN2A • EP300 • FBXL16 • MYD88 • PIM1 • PRDM1 • TMB

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia (ASH 2025) - P=N/A | "The patients received a TKI-based [imatinib or flumatinib (a second-generation TKI)] standardized VIP regimen (Vincristine/Idarubicin/Prednisone), and eligible patients were recommended to undergo allo-HSCT. Notably, IKZF1 plus patients harboring T315I mutation constitute a subgroup with dismal survival, likely associated with the down-regulation of p53 pathways, and they would benefit from allo-HSCT. Conversely, IKZF1 plus cases without ABL1 mutations exhibit a markedly favorable prognosis."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1 • IKZF1

Efficacy and safety of mini-CVD combined with venetoclax and azacitidine in acute leukemia of ambiguous lineage: A single-center retrospective study (ASH 2025) - " We retrospectively analyzed the clinical characteristics, efficacy, and safety of 13 newly diagnosed ALAL patients who received induction therapy with the mini-CVD regimen (cyclophosphamide, vincristine, dexamethasone) combined with venetoclax and azacitidine . Our data demonstrated that this regimen showed a high CR rate, with manageable toxicity, offering a promising therapeutic approach for this rare and challenging leukemia subtype."

Retrospective data • Hematological Malignancies • Infectious Disease • Leukemia • Respiratory Diseases • IKZF1 • KMT2A • RUNX1

Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience (ASH 2025) - "In general, pediatric and pediatric-inspired regimens involve high cumulative doses of vincristine, glucocorticoids, and asparaginase (ASP), with most regimens adding an anthracycline (usually doxorubicin or daunorubicin), along with intensive and prolonged central nervous system prophylaxis...Four patients (10%) were CD20 positive, and three of them received rituximab (3-7 doses in total). Five received blinatumomab prior to transplant for MRD eradication, and 16 underwent allogeneic transplantation in first complete remission (CR1)... Our single-center experience in AYA-ALL patients aged 18–40 treated with the pediatric- inspired GMALL protocol demonstrates favorable survival outcomes and good tolerability. These real-world findings align with previously reported GMALL clinical trial data and are comparable to outcomes seen with more intensive pediatric regimens in this age group."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Pancreatitis • CD20

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab (ASH 2025) - "The MD Anderson Cancer Center (MDACC) also has published a regimen incorporating Blin into hyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) therapy as induction and consolidation for adults with Ph neg B-ALL...Two doses of rituximab were included in each of the first 4 cycles of therapy when CD20 expression was identified on ≥20% of blasts at diagnosis. Intrathecal prophylaxis consisted of alternating doses of methotrexate and cytarabine, with a goal of administering 2 doses per cycle for a minimum of 8 doses... The addition of Blin to front-line hyperCVAD chemotherapy is associated with excellent RFS in adults with standard-risk ALL, but patients with HR genotypes remain at risk of relapse within one year of treatment initiation. This demonstrates a need for further iteration on this approach to better mitigate the risk of relapse. Because alloHCT remains the best approach to sustain long-term definitive disease control, it remains especially..."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • CD20 • CRLF2 • JAK2 • KMT2A • TP53